A study to learn how well tucatinib plus trastuzumab works for treating participants with metastatic colorectal cancer, and how safe it is: a plain language summary of the MOUNTAINEER study. | Future Oncol;20(8): 409-421, 2024 Mar. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

A study to learn how well tucatinib plus trastuzumab works for treating participants with metastatic colorectal cancer, and how safe it is: a plain language summary of the MOUNTAINEER study.

Strickler, John H; Bekaii-Saab, Tanios S.

Affiliation

Strickler JH; Duke University Medical Center, Durham, NC, USA.
Bekaii-Saab TS; Mayo Clinic Arizona, Phoenix, AZ, USA.

Future Oncol ; 20(8): 409-421, 2024 Mar.

Article in En | MEDLINE | ID: mdl-37941353

Subject(s)
Key words

HER2+; drug development; gastrointestinal/colorectal; novel therapy

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxazoles / Quinazolines / Rectal Neoplasms / Colonic Neoplasms Limits: Adult / Humans Language: En Journal: Future Oncol Year: 2024 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxazoles / Quinazolines / Rectal Neoplasms / Colonic Neoplasms Limits: Adult / Humans Language: En Journal: Future Oncol Year: 2024 Document type: Article Affiliation country: Country of publication: